Δ7-mesembrenone (delta-7-mesembrenone) is a naturally occurring Kanna alkaloid and a positional isomer of mesembrenone. It appears in some authenticated Sceletium plant samples, can change during post-harvest processing, and is sometimes used as a marker in commercial extracts. Yet its name is often attached to claims that the research did not test.
The evidence is much narrower than online descriptions suggest. Published work includes plant chemistry, fermentation experiments, analytical separation, a cell-based comparison of two multi-constituent extracts, and computer docking. This review did not identify a controlled human pharmacokinetic or clinical study of isolated Δ7-mesembrenone. Results for whole Kanna, mesembrenone, mesembrine, or a Δ7-rich extract therefore cannot be relabeled as results for the purified molecule.
This guide is educational, nonmedical, and intended for adults 21 and older. It provides no serving instructions and does not recommend using Kanna or any isolated alkaloid to diagnose, treat, cure, or prevent a condition.
The central finding: Δ7-mesembrenone is chemically real and analytically important, but its compound-specific human pharmacology remains largely uncharacterized. The best evidence concerns where it appears, how processing can change it, and why laboratories must distinguish it from mesembrenone and related isomers.
Δ7-mesembrenone in one minute
- Δ7-mesembrenone is one member of the mesembrine-type alkaloid family; it is not a synonym for Kanna.
- It shares the formula C17H21NO3 and nominal molecular mass of mesembrenone, but the double bond occupies a different position.
- The same mass does not prove the same identity. Chromatographic separation and an appropriate reference standard matter.
- Its abundance varies among populations, plant parts, cultivation conditions, processing methods, and extracts.
- One 2009 experiment found a large rise in Δ7-mesembrenone during a defined simulated fermentation; later studies show that other processes can produce different profiles.
- A 2022 study used LC-MS metabolomics and computer docking. Docking predicts possible fit in a model; it does not demonstrate binding or an effect in a person.
- A 2018 cell study tested a Δ7-mesembrenone-rich extract, not purified Δ7-mesembrenone. Polyphenols and other constituents were also present.
- No controlled human study located for this review isolated the molecule’s absorption, metabolism, clinical effects, or interaction risk.
What is Δ7-mesembrenone?
Δ7-mesembrenone is a nitrogen-containing alkaloid reported in plants of the Sceletium genus. Kanna is generally identified in the research literature as Sceletium tortuosum; current botanical references also use the accepted name Mesembryanthemum tortuosum L. The compound belongs to the broad mesembrine-type family that also includes mesembrine, mesembrenone, mesembrenol, mesembranol, and several epimers or derivatives.
The “Δ7” prefix identifies the position of a carbon-carbon double bond. Some modern papers call ordinary mesembrenone “Δ6-mesembrenone” to make the distinction explicit. Older literature may simply say mesembrenone. Authors do not always use the same numbering conventions, so identity should be checked against the reported structure, retention time, fragments, and standard—not inferred from a shortened name.
Commercial reference standards commonly list a formula of C17H21NO3 and relative molecular mass near 287.35. A reagent standard, however, is not evidence that a botanical product contains a particular concentration, stereochemical form, or bioavailable amount. It is an analytical tool.
Δ7-mesembrenone is not mesembrenone
Δ7-mesembrenone and mesembrenone are positional isomers. They have the same elemental formula and exact mass, but the double bond is located in a different part of the ring system. That seemingly small structural difference can change chromatographic retention, fragmentation, stability, enzyme recognition, and target interactions.
This distinction is essential when reading older pharmacology. The widely cited SERT and PDE4 values reported by Harvey and colleagues in 2011 were for purified mesembrenone, not identified as Δ7-mesembrenone. Those values cannot be copied onto Δ7-mesembrenone merely because the molecules share a formula. Kiody’s mesembrenone evidence guide reviews that compound separately.
| Research object | What was studied | What it can support | What it cannot establish |
|---|---|---|---|
| Authenticated plant material | A variable botanical mixture from a defined species, population, and plant part | Occurrence and relative chemistry of the sampled material | The profile of every Kanna product |
| Fermented Kanna | Plant material subjected to one documented process | Before-and-after change under those exact conditions | A universal “fermented Kanna” profile |
| Δ7-rich extract | A mixture enriched in, or characterized by, Δ7-mesembrenone | Results for that complete tested extract | The effect of purified Δ7-mesembrenone |
| Purified Δ7-mesembrenone | One structurally defined molecule | Compound-specific results when actually tested | Whole-plant or extract effects |
| Mesembrenone | A positional isomer with the same formula | Results for mesembrenone | Automatic substitution for Δ7-mesembrenone |
Where does Δ7-mesembrenone occur?
Its occurrence is not uniform. Reddy, Stander, Stafford, and Makunga collected Sceletium from 12 Western Cape localities in 2020, confirmed taxonomy, lodged voucher specimens, and analyzed 107 samples. Their LC-MS metabolomics study found marked differences among species and populations. High relative levels of Δ7-mesembrenone were associated with some S. tortuosum populations, including Kannaland and Ladismith 1, while other populations had different alkaloid patterns.
The study used silica-dried leaves extracted in methanol and high-throughput instrumental analysis. Most analyses used ten replicates; three populations had only three. This is strong evidence for geographic and chemical variability in the sampled material, but it is not a retail-product survey and does not provide a universal concentration range for Kanna.
The authors reported funding from the National Research Foundation of South Africa and research grants to team members. They also published a corrigendum correcting a figure reference. The correction does not erase the population-level chemical finding, but it is part of the record readers should know.
Primary source: Reddy et al., 2022; correction: 2022 corrigendum.
Plant part and cultivation can change the profile
Faber and colleagues grew S. tortuosum hydroponically under multiple soilless media and fertigation regimes. Their measurements showed that alkaloid patterns differed between roots and shoots: roots tended to contain more Δ7-mesembrenone and mesembrenone, while shoots contained more mesembrine. The work also found that cultivation conditions changed measured alkaloid concentrations.
That result does not mean every root product is “high Δ7” or that shoots lack it. It means plant part is a material variable that must be named. A certificate that reports “Kanna alkaloids” without the plant part, matrix, units, and method omits information needed to interpret the result.
Primary source: Faber et al., 2020.
Does fermentation create Δ7-mesembrenone?
It can increase Δ7-mesembrenone under some conditions, but “fermentation always creates more” is too broad. Patnala and Kanfer simulated a traditional kougoed preparation and measured alkaloids before and after processing. Mesembrine fell from 1.33% to 0.05% in their initial experiment, while Δ7-mesembrenone increased. Follow-up experiments indicated that an aqueous environment, light, and heat contributed to the transformation.
This was a chemical processing study, not a human trial. The starting plant, vessel, moisture, temperature, illumination, duration, oxygen, and microbial community define the result. It does not prove that every fermented batch follows the same pathway or reaches the same final ratio.
Other controlled work has produced different directions for related alkaloids. Chen and Viljoen reported increased mesembrine and decreased mesembrenone under their fermentation conditions. A 2024 investigation found time-dependent differences between sterile and naturally inoculated processes. Taken together, the literature supports process sensitivity, not one universal conversion rule.
Primary sources: Patnala and Kanfer, 2009, Chen and Viljoen, 2019, and Koroleva et al., 2024.
Fermentation is not one standardized process
| Variable | Why it matters | What a defensible report should state |
|---|---|---|
| Starting chemotype | Initial alkaloid ratios can differ greatly among populations | Authenticated source, harvest, and baseline profile |
| Plant part | Roots and shoots can have different profiles | Material included and dry- or fresh-weight basis |
| Water, heat, light, and oxygen | Each can alter degradation and isomerization pathways | Temperature, duration, moisture, light, and vessel conditions |
| Microorganisms | Natural and controlled inoculation may produce different chemistry | Sterile control, inoculum, and microbial characterization when available |
| Analytical method | Coelution or isomer confusion can change the apparent result | Separation method, standard, calibration, and units |
“Fermented” is therefore a preparation category, not a certificate of a particular Δ7-mesembrenone concentration. Batch-specific testing is needed when the concentration is material to a scientific or product claim.
What did the 2018 cell study test?
Bennett and colleagues compared two chemically different S. tortuosum extracts in cellular models: one described as high in mesembrine and another described as high in Δ7-mesembrenone and polyphenols. The high-Δ7 extract showed strong antioxidant activity in the test systems, while the high-mesembrine extract produced stronger anti-inflammatory and cytoprotective findings. At the highest tested concentration, the Δ7-rich extract also reduced astrocyte viability and mitochondrial reductive capacity.
These results are often summarized as if purified Δ7-mesembrenone were tested. It was not. The Δ7-rich material was a complex extract, and the authors explicitly associated it with a different polyphenol profile. The design cannot determine whether Δ7-mesembrenone, polyphenols, another alkaloid, or an interaction among constituents drove any result.
The cells were not people, and a concentration applied to cultured cells is not a human exposure. The study can generate hypotheses about composition-dependent extract behavior. It cannot establish antioxidant benefit, clinical safety, or toxicity of isolated Δ7-mesembrenone.
Primary source: Bennett et al., 2018.
What does computer docking show?
The 2022 Reddy study also docked tentatively identified alkaloids into structural models related to GABA-A, serotonin transport, and acetylcholinesterase. Δ7-mesembrenone produced model scores in all three analyses, including predicted fits of −5.882 kcal/mol at the GABA-A site, −6.665 or −6.152 in the serotonin-transporter model depending on the annotated feature, and −8.348 in the acetylcholinesterase model.
Those numbers are computational rankings under one model. They are not measured Ki, IC50, receptor occupancy, brain concentration, or clinical effect. Docking does not reproduce membrane dynamics, metabolism, free concentration, stereochemistry, or allosteric behavior. It is useful for prioritizing experiments, not for claiming that Δ7-mesembrenone acts like a benzodiazepine, SSRI, or acetylcholinesterase medicine.
The same paper noted that prior laboratory work found little to no GABA-A binding inhibition from isolated mesembrine, mesembrenone, and mesembrenol, while a standardized multi-constituent extract showed much more. Δ7-mesembrenone itself was not isolated and validated in that assay. Prediction and direct measurement must remain separate.
Has Δ7-mesembrenone been tested at SERT or PDE4?
Direct compound-specific evidence is sparse. Harvey and colleagues reported SERT and PDE4 results for mesembrine, mesembrenone, and mesembrenol. Their paper is frequently cited in discussions of all Kanna alkaloids, but it did not establish a Δ7-mesembrenone SERT affinity or PDE4 potency that can be transferred to this isomer.
The 2022 docking study predicted possible interaction with a serotonin-transporter structure. A prediction is not a transporter assay. This review did not locate an independently replicated, purified Δ7-mesembrenone study reporting validated SERT uptake inhibition, binding affinity, or PDE4 subtype potency. Until such data exist, precise target claims should be labeled unknown rather than borrowed from mesembrenone.
For the compound-specific assay that is available for the other isomer, see Harvey et al., 2011.
Has isolated Δ7-mesembrenone been studied in humans?
This review did not identify a controlled human study that administered analytically verified, purified Δ7-mesembrenone. No validated human Cmax, Tmax, half-life, clearance, oral bioavailability, metabolite profile, target engagement, dose-response curve, or interaction magnitude has been established.
Small human studies of Kanna have tested named multi-constituent extracts. For example, a 37-participant randomized tolerability study and a 16-participant crossover imaging study examined standardized extracts. Those results belong to those products and batches. They do not reveal what isolated Δ7-mesembrenone does in people, and they do not prove that any retail extract with a different alkaloid ratio will behave the same way.
Human extract sources: Nell et al., 2013 and Terburg et al., 2013.
What is known about metabolism and pharmacokinetics?
Very little is compound-specific. Meyer and colleagues characterized metabolism of mesembrine and mesembrenone using rat urine, pooled human-liver preparations, and recombinant enzymes. Manda and colleagues quantified mesembrine and mesembrenone in mouse plasma. Neither study established the pharmacokinetics of Δ7-mesembrenone.
Because positional isomers can be handled differently by enzymes, transporters, and chromatographic systems, the metabolism of mesembrenone cannot simply be assigned to Δ7-mesembrenone. It is plausible that overlapping routes exist, but plausibility is not a measured metabolite map.
Key missing work includes incubations with authenticated Δ7-mesembrenone, metabolite structural confirmation, reaction-phenotyping with human enzymes, validated plasma methods, and a controlled living-human study. Without those pieces, claims about onset, duration, bioavailability, or “stronger” effects are speculative.
How laboratories distinguish the isomers
A nominal mass signal cannot distinguish Δ7-mesembrenone from mesembrenone because the isomers have the same formula. A credible method separates compounds before detection and verifies identity with more than one piece of evidence.
High-performance or ultra-high-performance liquid chromatography can provide retention separation. Tandem mass spectrometry adds fragmentation patterns; high-resolution instruments improve exact-mass assignments. Nuclear magnetic resonance can provide stronger structural confirmation for purified material. Nonaqueous capillary electrophoresis–mass spectrometry has also been used to resolve isobaric and stereochemically related Sceletium alkaloids.
Reddy and colleagues combined LC-MSE, SWATH-MS2, feature-based molecular networking, reference information, and retention patterns. They still described many identities as tentative because natural-product libraries remain incomplete. That wording matters: a feature annotation is not always the same as identification against an authenticated standard.
Analytical sources: Reddy et al., 2022 and Kanna alkaloid separation by capillary electrophoresis–MS.
What a Δ7-mesembrenone COA should show
A useful certificate of analysis identifies the lot, matrix, plant part or extract type, and units. It reports Δ7-mesembrenone separately rather than hiding it inside “total alkaloids.” The method should demonstrate that Δ7-mesembrenone is separated from mesembrenone and other same-mass or closely related compounds.
Look for the analytical platform, reference-standard identity and purity, calibration range, detection or quantification limit, and whether the result is reported on a dry-weight, extract-weight, liquid-volume, or finished-unit basis. “Not detected” means below a method’s reporting threshold; it does not mean absolute zero.
A percentage without the denominator is not interpretable. A percentage of total alkaloids is different from a percentage of the finished material. Product comparisons require the same units and a sufficiently selective method.
What the key studies actually tested
| Study | Design and sample | Tested material | Main contribution | Main limit |
|---|---|---|---|---|
| Patnala & Kanfer, 2009 | Before-and-after simulated kougoed preparation plus stability experiments | Plant material and alkaloid solutions | Process-dependent mesembrine-to-Δ7 shift | One starting material and defined laboratory conditions; no human outcomes |
| Bennett et al., 2018 | Cell-based antioxidant, inflammatory, and viability experiments | Two multi-constituent extracts, one Δ7-rich and polyphenol-rich | Extract composition associated with different cellular results | Cannot assign results to purified Δ7-mesembrenone |
| Faber et al., 2020 | Hydroponic cultivation under varied media and fertigation | Roots and shoots of cultivated S. tortuosum | Plant-part and cultivation variability | Area-percent chemistry is not human exposure |
| Reddy et al., 2022 | 107 samples from 12 localities; LC-MS metabolomics and molecular networking | Silica-dried leaves from four Sceletium species | Population-specific chemistry and tentative isomer annotation | Not a product survey; docking is predictive |
| Koroleva et al., 2024 | Time-course comparison of controlled processing conditions | Fermenting plant material | Microbial and time-dependent profile changes | Process-specific; no clinical evidence |
Δ7-mesembrenone, medicines, and interaction uncertainty
There is not enough compound-specific evidence to quantify interactions. The docking paper does not prove SERT, GABA-A, or acetylcholinesterase activity in people. The absence of a human pharmacokinetic study also means no reliable systemic exposure or enzyme-interaction threshold is available.
This uncertainty does not prove universal safety. Kanna extracts may contain other alkaloids with measured monoamine-related activity, and composition varies. People using serotonergic medicines, monoamine oxidase inhibitors, stimulants, sedatives, or other centrally active drugs should discuss Kanna with the prescribing clinician or pharmacist rather than changing medication or combining products independently.
High fever, severe agitation or confusion, repeated clonus, marked rigidity, seizure, collapse, breathing difficulty, or inability to wake requires urgent medical attention. This is symptom-recognition information, not an interaction prediction or home-treatment protocol.
Claims the evidence does not support
| Claim | Evidence-based reading |
|---|---|
| “Δ7-mesembrenone and mesembrenone are the same.” | Incorrect. They are positional isomers with the same formula but different structures. |
| “Mesembrenone SERT and PDE4 values apply to Δ7.” | Unsupported. The purified compounds must be tested separately. |
| “Fermentation always raises Δ7-mesembrenone.” | Too broad. Results depend on starting chemotype and process conditions. |
| “A Δ7-rich extract proves what pure Δ7 does.” | Incorrect. The tested extract contained multiple alkaloids, polyphenols, and other constituents. |
| “Docking proves antidepressant or anti-anxiety effects.” | Incorrect. Docking is a computer prediction, not a human clinical outcome. |
| “High antioxidant activity proves health benefit.” | Incorrect. A chemical or cell assay does not establish a clinical benefit. |
| “No human study means the molecule is safe.” | Incorrect. Missing evidence is uncertainty, not proof of safety or harm. |
| “Total alkaloids tells you the Δ7 content.” | Incorrect. Individual compounds require selective, compound-specific measurement. |
Important evidence gaps
- Replicated receptor, transporter, and enzyme assays using authenticated purified Δ7-mesembrenone.
- Direct comparison with mesembrenone under the same assay conditions.
- Validated human-liver metabolism and enzyme-interaction experiments.
- Living-human plasma pharmacokinetics, metabolites, bioavailability, and clearance.
- Controlled human safety, target-engagement, and clinical-outcome studies of the isolated compound.
- Independent studies separating Δ7-mesembrenone from polyphenols and other alkaloids in extract-level findings.
- Standardized fermentation studies across authenticated chemotypes and plant parts.
- Routine reference-standard methods that report isomer selectivity, uncertainty, and matrix effects.
These gaps are the scientific story. Δ7-mesembrenone is not an unstudied name—it is well enough documented to require analytical attention—but its human pharmacology remains far behind its visibility in product marketing.
Frequently asked questions
Is Δ7-mesembrenone the same as mesembrenone?
No. They share a formula and molecular mass but differ in the position of a double bond. Results for one isomer should not be transferred to the other.
Is Δ7-mesembrenone naturally present in Kanna?
It has been identified in authenticated Sceletium material, but abundance varies among populations, plant parts, and processing conditions. Its presence or concentration in a product requires batch-specific testing.
Does fermentation increase Δ7-mesembrenone?
It did in the 2009 simulated kougoed study, but other research shows that alkaloid changes depend on starting chemistry, water, light, heat, microorganisms, time, and the analytical method. “Fermented” does not guarantee one profile.
Does Δ7-mesembrenone inhibit SERT or PDE4?
Compound-specific evidence is insufficient. Mesembrenone has laboratory SERT and PDE4 data, but those values cannot be assigned to its Δ7 positional isomer. Computer docking is not a direct activity assay.
Has isolated Δ7-mesembrenone been tested in people?
This review did not locate a controlled human pharmacokinetic or outcome study of purified Δ7-mesembrenone. Human Kanna research has tested multi-constituent extracts.
Is a high-Δ7 Kanna extract the same as pure Δ7-mesembrenone?
No. An extract contains other alkaloids and non-alkaloid constituents. A 2018 high-Δ7 extract was also described as polyphenol-rich, so its cellular results cannot be assigned to one molecule.
Can LC-MS distinguish Δ7-mesembrenone from mesembrenone?
Only if the method provides adequate separation and identity evidence. Same-mass isomers can be confused when a method relies on nominal mass alone. Retention behavior, diagnostic fragments, authenticated standards, and sometimes NMR are important.
What should a Δ7-mesembrenone COA include?
It should identify the lot and matrix, report Δ7 separately with clear units, name the method and reference standard, and show that mesembrenone and other relevant isomers were adequately distinguished.
Bottom line
Δ7-mesembrenone is a distinct Kanna alkaloid, not another spelling of mesembrenone and not a substitute for the whole botanical. Research supports variable natural occurrence, plant-part differences, process-dependent formation, and the need for isomer-selective testing. A Δ7-rich extract has produced composition-dependent findings in cells, and docking has generated testable hypotheses.
What the evidence does not yet provide is equally important: validated human pharmacokinetics, direct human effects, a compound-specific interaction profile, or permission to transfer mesembrenone’s SERT and PDE4 values to Δ7-mesembrenone. Until those gaps are filled, the most accurate description is chemically documented, analytically challenging, and pharmacologically uncertain.
Last reviewed: September 16, 2026. This article is educational and nonmedical. Adults 21+ only.